Annexin A13 promotes tumor cell invasion <i>in vitro</i> and is associated with metastasis in human colorectal cancer

Jiang, Guozhong; Wang, Pengju; Wang, Weiwei; Li, Wencai; Dai, Liping; Chen, Kuisheng

doi:10.18632/oncotarget.15523

Cited by 20 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are relatively few studies on other members of the Annexin family in ovarian cancer, but it has been demonstrated that they are dysregulated in other malignant tumors, such as breast cancer, gastric cancer, colorectal cancer, and pancreatic cancer [44–49]. The results of our database analyses showed that the mRNA expression levels of ANXA5, ANXA6 , ANXA7 and ANXA13 were downregulated.…”

Section: Discussionmentioning

confidence: 79%

Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins

et al. 2019

View full text Add to dashboard Cite

Background Annexins are involved in vesicle trafficking, cell proliferation and apoptosis, but their functional mechanisms in ovarian cancer remain unclear. In this study, we analyzed Annexins in ovarian cancer using different databases and selected Annexin A8 (ANXA8), which showed the greatest prognostic value, for subsequent validation in immunohistochemical (IHC) assays. Methods The mRNA expression levels, genetic variations, prognostic values and gene–gene interaction network of Annexins in ovarian cancer were analyzed using the Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), cBioPortal, Kaplan–Meier plotter and GeneMANIA database. ANXA8 was selected for analyzing the biological functions and pathways of its co-expressed genes, and its correlation with immune system responses via the Database for Annotation, Visualization, and Integrated Discovery (DAVID) and the TISIDB database, respectively. We validated the expression of ANXA8 in ovarian cancer via IHC assays and analyzed its correlation with clinicopathological parameters and prognosis. Results ANXA2/3/8/11 mRNA expression levels were significantly upregulated in ovarian cancer, and ANXA5/6/7 mRNA expression levels were significantly downregulated. Prognostic analysis suggested that significant correlations occurred between ANXA2/4/8/9 mRNA upregulation and poor overall survival, and between ANXA8/9/11 mRNA upregulation and poor progression-free survival in patients with ovarian serous tumors. Taken together, results suggested that ANXA8 was most closely associated with ovarian cancer tumorigenesis and progression. Further analyses indicated that ANXA8 may be involved in cell migration, cell adhesion, and vasculature development, as well as in the regulation of PI3K-Akt, focal adhesion, and proteoglycans. Additionally, ANXA8 expression was significantly correlated with lymphocytes and immunomodulators. The IHC results showed that ANXA8 expression was higher in the malignant tumor group than in the borderline and benign tumor groups and normal ovary group, and high ANXA8 expression was an independent risk factor for survival and prognosis of ovarian cancer patients ( P = 0.013). Conclusions Members of the Annexin family display varying degrees of abnormal expressions in ovarian cancer. ANXA8 was significantly highly expressed in ovarian cancer, and high ANXA8 expression was significantly correlated with poor prognosis. Therefore, ANXA8 is a high candidate as a novel biomarker and therapeutic target for ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 79%

Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In lung cancer cells, ANXA2 contributed to cisplatin resistibility via JNK-p53 pathway activation [21]. In vitro, overexpression of ANXA13 facilitated colorectal cancer cell invasion [11]. As reported, ANXA13 ectopic overexpression promoted the sensitivity of breast cancer cells to therapy with rapamycin [22].…”

Section: Discussionmentioning

confidence: 66%

“…Except it, another 11 annexin family members (ANXA1-11) are found in human [10]. These 12 members are implicated in a series of cellular processes containing membrane scaffolding, cell signaling, and apoptosis [11]. ANXA13 has two isoforms (ANXA13a and ANXA13b), which were primordially found in the screening of myristoylated gutspecific genes [12].…”

Section: Introductionmentioning

confidence: 99%

“…Overexpression of ANXA4 has been identified in lung cancer, suggesting that ANXA4 might be a potential target for therapeutic intervention in lung cancer [14]. According to the study of Jiang et al [11], ANXA13 facilitated human colorectal cancer cell invasion. K€ alsch et al [15] identified ANXA13 as a biomarker for intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Annexin A13 predicts poor prognosis for lung adenocarcinoma patients and accelerates the proliferation and migration of lung adenocarcinoma cells by modulating epithelial–mesenchymal transition

Xue

Zhang

Zheng

et al. 2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

This study aimed to investigate the role of ANXA13 in lung adenocarcinoma (LUAD) growth, migration, and the underlying mechanisms. Firstly, in the TCGA dataset for LUAD, ANXA13 is found to be highly expressed in patients with LUAD and high expression of ANXA13 predicted poor outcomes in LUAD patients. Consistently, the data of qRT‐PCR showed that the expression of ANXA13 was higher in LUAD cell lines (Calu‐3, LTEP‐a‐2, and NCI‐H1395) than that in normal lung cell line BEAS2B. Then, we performed gain‐ and loss of function of ANXA13 in NCI‐H1395 and Calu‐3 cells, respectively. The results displayed that deficiency of ANXA13 suppresses cell proliferation, invasion, and migration in Calu‐3 cells and overexpression of ANXA13 augments cell proliferation, invasion, and migration in NCI‐H1395 cells. Finally, it was found that silencing of ANXA13 obviously raised the protein expression levels of E‐cadherin and reduced the protein levels of N‐cadherin, Vimentin, and Snail in Calu‐3 cells whereas overexpression of ANXA13 obviously receded the protein expression levels of E‐cadherin and enhanced the protein levels of N‐cadherin, Vimentin, and Snail in NCI‐H1395 cells. This study analyzed the biological effects of ANXA13 in LUAD cells, indicating that ANXA13 could regard as a therapeutic target for LUAD.

show abstract

“…However, it too is associated with poor overall survival and poorer progression-free survival particularly in late stage cancers. As such, Annexin A10 may be considered as a prognostic marker when present [115], similarly annexin A13 expression is associated with lymph node metastasis, however it is not associated with tumor stage or differentiation [116].…”

Section: Annexinsmentioning

confidence: 99%

Finding Needles in Haystacks: The Use of Quantitative Proteomics for the Early Detection of Colorectal Cancer

Gould¹,

Jamaluddin²,

Petit³

et al. 2019

Advances in the Molecular Understanding of Colorectal Cancer

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a common and treatable disease if diagnosed early. Current population screening programs are suboptimal, and consequently, there is a need for the development of new methodologies for early diagnosis of CRC. In the past 10 years, unprecedented technological advancements in the field of mass spectrometry (MS)-based proteomics have progressively increased the sophistication and utility of these investigations, leading to the draft mapping of the human proteome. These exciting studies have shaped our mechanistic understanding of the human genome and begun to provide us with a suite of novel biomarkers to predict the onset, progression and severity of many debilitating diseases. Thus, sophisticated MS workflows coupled with revolutionary protein quantification techniques hold promise for the field of MS-based plasma proteomics, particularly valuable in the context of early stage identification of curable CRC. However, within the last 40 years, no new plasma protein biomarkers of CRC have been translated into clinical practice. Here. we discuss the application of proteomic technologies within the field of CRC, highlighting contemporary MS-based plasma proteomic strategies that could be exploited to deliver on the promise of a panel of sensitive and specific plasma-based biomarkers with which to non-invasively detect early stage CRC.

show abstract

Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer

Cited by 20 publications

References 32 publications

Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins

Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins

Annexin A13 predicts poor prognosis for lung adenocarcinoma patients and accelerates the proliferation and migration of lung adenocarcinoma cells by modulating epithelial–mesenchymal transition

Finding Needles in Haystacks: The Use of Quantitative Proteomics for the Early Detection of Colorectal Cancer

Contact Info

Product

Resources

About